Last edition
News about "blood-brain barrier targeted therapy"
AviadoBio Advances AVB-101, Starts New Cohort in Phase 1/2 ASPIRE-FTD Trial
AviadoBio advances AVB-101 gene therapy with a new Phase 1/2 ASPIRE-FTD cohort, reporting encouraging early data, securing strategic funding and regaining full programme rights.
Blood-brain Barrier Targeted Therapy | 01/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members